Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

BACKGROUND: Alirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear. Every‐4‐weeks dosing of alirocumab may be appropriate for some patients in ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Rey, Jacques, Poitiers, Franck, Paehler, Tobias, Brunet, Aurélie, DiCioccio, A. Thomas, Cannon, Christopher P., Surks, Howard K., Pinquier, Jean‐Louis, Hanotin, Corinne, Sasiela, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937273/
https://www.ncbi.nlm.nih.gov/pubmed/27287699
http://dx.doi.org/10.1161/JAHA.116.003323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937273/
https://www.ncbi.nlm.nih.gov/pubmed/27287699
http://dx.doi.org/10.1161/JAHA.116.003323

Ejemplares similares